Connect your AI

UroGen Pharma URGN Total Liabilities

Total Liabilities at other companies

Bristol-Myers SquibbBMY

$66.37B-11.5%

PfizerPFE

$3.41B-97.1%

Johnson & JohnsonJNJ

$119.71B+3.6%

Merck & Co.MRK

$229M—

ImmunityBio, Inc.IBRX

$1.52B+69.5%

Tyra Biosciences, Inc.TYRA

$24.47M+22.7%

Other financials

Income statement

Revenue$51.0M+152%

Gross profit$11.6M—

Operating income-$22.8M—

Net income-$23.6M+46.2%

EPS (diluted)-$1.17—

Balance sheet

Cash & equivalents$110.0M+5.7%

Total debt$197.1M+56.0%

Total equity-$124.3M-167%

Total assets$253.7M+2.5%

Cash flow

Operating cash flow-$45.3M-7.8%

CapEx$54.0K+22.7%

Free cash flow-$45.4M-7.8%

Valuation

Market cap$1.73B+71.7%

Enterprise value$1.81B+80.9%

P/S12.3×+1.3×

Profitability

Gross margin89.7%—

Operating margin-329.7%—

Net margin-94.8%-25.6pp

FCF margin-118.2%+1.3pp

Returns & leverage

Return on equity-211.6%—

Debt / equity4.8×—

Current ratio4.7×-1.0×

Where this comes from

Reported directly by UroGen Pharma in its filing.

Tagged under the XBRL concept us-gaap:Liabilities.

The official record: UroGen Pharma’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about UroGen Pharma's total liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is UroGen Pharma's total liabilities?: UroGen Pharma (URGN) reported total liabilities of $377.94M in Q1 2026.
How has UroGen Pharma's total liabilities changed year-over-year?: UroGen Pharma's total liabilities increased by 28.5% year-over-year, from $294.08M to $377.94M.
What is the long-term trend for UroGen Pharma's total liabilities?: Over 5 years (2020 to 2025), UroGen Pharma's total liabilities has grown at a 64.2% compound annual growth rate (CAGR), from $25.65M to $305.93M.
What does total liabilities mean?: The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.